Cell MedX (CMXC) Widens Scope for Breakthrough Technology
By RYAN ALLWAY December 13th, 2016
Source: SECFilings.com
Cell MedX Corp. (OTCQB: CMXC), a development-stage biotech company focused on harnessing the power of microcurrent technologies to address numerous health conditions, recently expanded the potential addressable market for its eBalance Pro from diabetes to Parkinson’s disease, high blood pressure, and other health conditions. The move comes after early stage observations, and testimonials from volunteer subjects, revealed a much wider potential for the technology beyond their original sole focus on diabetes treatment.
In this article, we will look at the company’s decision to broaden the market scope for its eBalance technology, as well as some near-term catalysts that could boost the stock.
Broadening the Focus
Cell MedX Corp.’s discovery phase trial in February 2015 found that its eBalance Technology improved insulin sensitivity and upregulated glycolytic processes resulting in enhanced transport as well as utilization of glucose during a single treatment. With the diabetes devices market expected to reach $35.5 billion by 2024, according to Grand View Research, an approved product that increases insulin sensitivity could quickly become a blockbuster therapeutic device.
Since then, further investigations led the company to broaden its focus to include conditions like Parkinson’s disease and high blood pressure, where the company believes microcurrent technology could prove efficacious. GBI Research believes that Parkinson’s disease could be a $3.2 billion market by 2021, while Technavio expects hypertension drugs to generate more than $32 billion in sales by 2020. These are significant additional end markets for the company’s breakthrough technology.
The company’s short-term goal is to obtain approval for the eBalance technology to treat pain and address general wellness. The company aims to initially deploy pain management solutions utilizing qualified supervisory protocols, with advanced therapies for related conditions to be offered by clinicians. The team would then apply to market and distribute the device to treat a variety of other conditions – including diabetes and Parkinson’s disease – on an individualized basis, employing appropriate supervisory protocols, while potentially partnering with research institutions to further develop areas of investigation into a number of conditions where the technology has shown potential for future use.
Innovative Technology
Cell MedX Corp.’s eBalance Pro is based on a fully software-driven microcurrent technology. Using cutting-edge software, the device identifies specific frequencies for microcurrent application through the use of a bio-feedback algorithm that identifies and delivers personalized frequencies to provide optimal outcomes which address specific, and in most instances, painful conditions.
Upon the successful completion of the upcoming clinical trials, the eBalance Pro would be the only microcurrent therapy developed to treat specific medical conditions on an individualized basis. The software-driven nature of the device would also enable results to be achieved more quickly than the lengthy time required by currently available microcurrent devices typically marketed for physiotherapy purposes. If successful, the eBalance Pro would hold a significant competitive advantage when marketed as medical device specifically capable of addressing a growing list of conditions.
Microcurrent technologies have been shown to have potential benefits across a range of medical conditions. Several studies have acknowledged that microcurrents appear to play a significant role in the healing process and can promote healing in a variety of bone and skin lesions, while other studies have shown that microcurrents can have a significant impact on reducing lower back pain and other conditions.
To read the full article visit - https://cellmedx.com/cell-medx-cmxc-widens-scope-breakthrough-technology/